HC Wainwright Raises Compass Therapeutics (NASDAQ:CMPX) Price Target to $24.00

Compass Therapeutics (NASDAQ:CMPX) had its price objective upped by equities researchers at HC Wainwright from $10.00 to $24.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

Several other brokerages have also issued reports on CMPX. Leerink Partners upgraded shares of Compass Therapeutics from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $4.00 to $6.00 in a research report on Wednesday. Leerink Partnrs raised Compass Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, April 1st. Guggenheim reissued a “buy” rating and set a $12.00 price target on shares of Compass Therapeutics in a report on Wednesday. Wedbush reaffirmed an “outperform” rating and issued a $8.00 price objective on shares of Compass Therapeutics in a research note on Tuesday, April 1st. Finally, D. Boral Capital reiterated a “buy” rating and set a $32.00 price objective on shares of Compass Therapeutics in a research note on Tuesday, April 1st. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $13.38.

Compass Therapeutics Trading Down 9.0 %

Shares of CMPX opened at $1.46 on Friday. The firm has a fifty day simple moving average of $2.76 and a two-hundred day simple moving average of $2.10. The firm has a market cap of $201.89 million, a PE ratio of -3.95 and a beta of 1.40. Compass Therapeutics has a 1-year low of $0.77 and a 1-year high of $4.08.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). As a group, research analysts forecast that Compass Therapeutics will post -0.36 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Squarepoint Ops LLC purchased a new position in Compass Therapeutics during the 4th quarter valued at approximately $35,000. Tang Capital Management LLC raised its stake in Compass Therapeutics by 225.4% during the fourth quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company’s stock valued at $8,555,000 after purchasing an additional 4,087,005 shares in the last quarter. ProShare Advisors LLC lifted its position in Compass Therapeutics by 49.0% during the fourth quarter. ProShare Advisors LLC now owns 28,722 shares of the company’s stock valued at $42,000 after purchasing an additional 9,451 shares during the last quarter. MPM Bioimpact LLC grew its stake in shares of Compass Therapeutics by 51.9% in the 4th quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company’s stock worth $12,423,000 after buying an additional 2,926,002 shares in the last quarter. Finally, Enavate Sciences GP LLC bought a new stake in shares of Compass Therapeutics in the 4th quarter worth about $11,293,000. Institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.